Skip to content
2000
Volume 32, Issue 4
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Although cutaneous melanoma accounts for only about 2% of skin cancers, its rapid progression makes it an aggressive skin cancer with a high mortality rate. As of 2018, the SEER database estimated that the 5-year overall survival (OS) rate is 29.8% in patients with stage IV disease at diagnosis in the United States. Non-cutaneous melanoma, including mucosal and uveal subtypes, carries a generally worse prognosis. Once considered refractory to conventional treatments, such as chemotherapy and radiation therapy, the advent of immunotherapy, including immune checkpoint inhibitors (ICIs), vaccines, and tumor-infiltrating lymphocytes (TIL), and of targeted therapy over the past decade has resulted in dramatic improvements in melanoma. Importantly, ICIs have resulted in long-term remission for patients with melanoma, thus introducing the possibility of a cure for some patients with metastatic disease. These include antibodies against programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1), cytotoxic T-lymphocyte antigen-4 (CTLA-4), and lymphocyte activation gene-3 (LAG-3). In this review, we will provide an overview of metastatic melanoma while focusing on its current pharmacologic armamentarium, toxicities of treatment, including ICIs and targeted therapy, and its therapeutic clinical strategies. The therapeutic advances presented in this review serve as the foundation for an ever-expanding repertoire of innovative approaches. These include mRNA vaccines, oncolytic viruses, bispecific engagers, oral immunomodulators, and novel cytokines. Adoptive cellular strategies are evolving to TILS transduced with conditional gene expression cassettes, as well as non-T cell approaches involving dendritic cells and natural killer (NK) cells. Targeted therapy strategies have broadened to include upstream components of RAS, other MAP kinase pathways, and HDAC inhibitors, among others. All these new paradigms translate into increasingly complex decision-making for the treatment team, a burden that is more than offset by the tremendous benefit for melanoma patients. This is truly the beginning of a new era.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128341628250519093548
2025-05-26
2026-03-01

  • From This Site

    /content/journals/cpd/10.2174/0113816128341628250519093548
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. TraceyE.H. VijA. Updates in melanoma.Dermatol. Clin.2019371738210.1016/j.det.2018.08.00330466690
     [Google Scholar]
  2. BalchC.M. GershenwaldJ.E. SoongS. Final version of 2009 AJCC melanoma staging and classification.J. Clin. Oncol.200927366199620610.1200/JCO.2009.23.479919917835
     [Google Scholar]
  3. Cancer stat facts: Melanoma of the skinAvailable from: https://seer.cancer.gov/statfacts/html/melan.html
  4. Explore cancer statisticsAvailable from: https://cancerstatisticscenter.cancer.org/#!/cancer-site/Melanoma%20of%20the%20skin
  5. WongV.K. LubnerM.G. MeniasC.O. Clinical and imaging features of noncutaneous melanoma.AJR Am. J. Roentgenol.2017208594295910.2214/AJR.16.1680028301211
     [Google Scholar]
  6. RobertC. LAG-3 and PD-1 blockade raises the bar for melanoma.Nat. Can.20212121251125310.1038/s43018‑021‑00276‑835121906
     [Google Scholar]
  7. LongL. ZhangX. ChenF. The promising immune checkpoint LAG-3: From tumor microenvironment to cancer immunotherapy.Genes Cancer201895-617618910.18632/genesandcancer.18030603054
     [Google Scholar]
  8. KarimkhaniC. GreenA.C. NijstenT. The global burden of melanoma: Results from the global burden of disease study 2015.Br. J. Dermatol.2017177113414010.1111/bjd.1551028369739
     [Google Scholar]
  9. TímárJ. VizkeletiL. DomaV. BarbaiT. RásóE. Genetic progression of malignant melanoma.Cancer Metastasis Rev.20163519310710.1007/s10555‑016‑9613‑526970965
     [Google Scholar]
  10. LawM.H. MacGregorS. HaywardN.K. Melanoma genetics: Recent findings take us beyond well-traveled pathways.J. Invest. Dermatol.201213271763177410.1038/jid.2012.7522475760
     [Google Scholar]
  11. BarrettJ.H. IlesM.M. HarlandM. Genome-wide association study identifies three new melanoma susceptibility loci.Nat. Genet.201143111108111310.1038/ng.95921983787
     [Google Scholar]
  12. AmosC.I. WangL.E. LeeJ.E. Genome-wide association study identifies novel loci predisposing to cutaneous melanoma.Hum. Mol. Genet.201120245012502310.1093/hmg/ddr41521926416
     [Google Scholar]
  13. BaxterA.J. HughesM.C. KvaskoffM. The Queensland Study of Melanoma: Environmental and genetic associations (Q-MEGA); Study design, baseline characteristics, and repeatability of phenotype and sun exposure measures.Twin Res. Hum. Genet.200811218319610.1375/twin.11.2.18318361720
     [Google Scholar]
  14. TímárJ. LadányiA. Molecular pathology of skin melanoma: Epidemiology, differential diagnostics, prognosis and therapy prediction.Int. J. Mol. Sci.20222310538410.3390/ijms2310538435628196
     [Google Scholar]
  15. AkbaniR. AkdemirK.C. AksoyB.A. Genomic classification of cutaneous melanoma.Cell201516171681169610.1016/j.cell.2015.05.04426091043
     [Google Scholar]
  16. LovlyC.M. DahlmanK.B. FohnL.E. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.PLoS One201274e35309e3532210.1371/journal.pone.003530922536370
     [Google Scholar]
  17. MaldonadoJ.L. FridlyandJ. PatelH. Determinants of BRAF mutations in primary melanomas.J. Natl. Cancer Inst.200395241878189010.1093/jnci/djg12314679157
     [Google Scholar]
  18. CastellaniG. BuccarelliM. ArasiM.B. BRAF mutations in melanoma: Biological aspects, therapeutic implications, and circulating biomarkers.Cancers20231516402610.3390/cancers1516402637627054
     [Google Scholar]
  19. AivazianK. AhmedT. El SharouniM.A. Histological regression in melanoma: Impact on sentinel lymph node status and survival.Mod. Pathol.202134111999200810.1038/s41379‑021‑00870‑234247192
     [Google Scholar]
  20. SharmaP. AllisonJ.P. The future of immune checkpoint therapy.Science20153486230566110.1126/science.aaa817225838373
     [Google Scholar]
  21. HemonP. Jean-LouisF. RamgolamK. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis.J. Immunol.201118695173518310.4049/jimmunol.100205021441454
     [Google Scholar]
  22. HopkinsA.C. Pancreatic cancer immunotherapy: T-cell receptor sequencing and personalized gene fusion vaccinesPhD. Thesis, The Johns Hopkins University, USA2017
     [Google Scholar]
  23. JohnsonD.B. FramptonG.M. RiothM.J. Targeted next generation sequencing identifies markers of response to PD-1 blockade.Cancer Immunol. Res.201641195996710.1158/2326‑6066.CIR‑16‑014327671167
     [Google Scholar]
  24. SnyderA. MakarovV. MerghoubT. Genetic basis for clinical response to CTLA-4 blockade in melanoma.N. Engl. J. Med.2014371232189219910.1056/NEJMoa140649825409260
     [Google Scholar]
  25. YaghmourG. PandeyM. IrelandC. Role of genomic instability in immunotherapy with checkpoint inhibitors.Anticancer Res.20163684033403827466509
     [Google Scholar]
  26. HuaG. CarlsonD. StarrJ.R. Tebentafusp-tebn: A novel bispecific T-cell engager for metastatic uveal melanoma.J. Adv. Pract. Oncol.202213771772310.6004/jadpro.2022.13.7.836199496
     [Google Scholar]
  27. VelhoT. Metastatic melanoma - A review of current and future drugs.Drugs Context2012201211710.7573/dic.21224224432031
     [Google Scholar]
  28. WolchokJ.D. Chiarion-SileniV. GonzalezR. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma.J. Clin. Oncol.202240212713710.1200/JCO.21.0222934818112
     [Google Scholar]
  29. Center for drug evaluation and research2014Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/202806Orig1s002.pdf
  30. KreidiehF.Y. TawbiH.A. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.Ther. Adv. Med. Oncol.2023151758835923118602710.1177/1758835923118602737484526
     [Google Scholar]
  31. AtkinsM.B. LotzeM.T. DutcherJ.P. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993.J. Clin. Oncol.19991772105211610.1200/JCO.1999.17.7.210510561265
     [Google Scholar]
  32. RosenbergS.A. YangJ.C. WhiteD.E. SteinbergS.M. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response.Ann. Surg.1998228330731910.1097/00000658‑199809000‑000049742914
     [Google Scholar]
  33. AndersonP.M. SorensonM.A. Effects of route and formulation on clinical pharmacokinetics of interleukin-2.Clin. Pharmacokinet.1994271193110.2165/00003088‑199427010‑000037955769
     [Google Scholar]
  34. AtzpodienJ. KörferA. EversP. Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: A phase II outpatient study.Mol. Biother.19902118262334534
     [Google Scholar]
  35. AtkinsM.B. Interleukin-2: Clinical applications.Semin. Oncol.2002293 Suppl. 7121710.1053/sonc.2002.33077
     [Google Scholar]
  36. KarpS.E. Low-dose intravenous bolus interleukin-2 with interferon-alpha therapy for metastatic melanoma and renal cell carcinoma.J. Immunother.1998211566110.1097/00002371‑199801000‑000079456437
     [Google Scholar]
  37. TagliaferriP. BarileC. CaragliaM. Daily low-dose subcutaneous recombinant interleukin-2 by alternate weekly administration: Antitumor activity and immunomodulatory effects.Am. J. Clin. Oncol.1998211485310.1097/00000421‑199802000‑000119499257
     [Google Scholar]
  38. MullardA. Restoring IL-2 to its cancer immunotherapy glory.Nat. Rev. Drug Discov.202120316316510.1038/d41573‑021‑00034‑633603157
     [Google Scholar]
  39. DiabA. TykodiS.S. DanielsG.A. Bempegaldesleukin plus nivolumab in first-line metastatic melanoma.J. Clin. Oncol.202139262914292510.1200/JCO.21.0067534255535
     [Google Scholar]
  40. AsciertoP.A. DaponteA. ParasoleR. Intermediate dose recombinant interferon-α as second-line treatment for patients with recurrent cutaneous melanoma who were pretreated with low dose interferon.Cancer20008971490149410.1002/1097‑0142(20001001)89:7<1490:AID‑CNCR11>3.0.CO;2‑V11013362
     [Google Scholar]
  41. DaponteA. SignorielloS. MaiorinoL. Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma.J. Transl. Med.20131113810.1186/1479‑5876‑11‑3823402397
     [Google Scholar]
  42. YoungA.M. MarsdenJ. GoodmanA. BurtonA. DunnJ.A. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma.Clin. Oncol.200113645846511824887
     [Google Scholar]
  43. BajettaE. Del VecchioM. NovaP. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-α2b in metastatic melanoma.Ann. Oncol.200617457157710.1093/annonc/mdl00716469753
     [Google Scholar]
  44. EtonO. LeghaS.S. BedikianA.Y. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial.J. Clin. Oncol.20022082045205210.1200/JCO.2002.07.04411956264
     [Google Scholar]
  45. RikerA.I. RossiG.R. MasihP. Combination immunotherapy for high-risk resected and metastatic melanoma patients.Ochsner J.201414216417424940124
     [Google Scholar]
  46. EgbertsF. GutzmerR. UgurelS. Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: A multicenter phase II DeCOG trial.Ann. Oncol.20112271667167410.1093/annonc/mdq64821220519
     [Google Scholar]
  47. GrignolV.P. OlenckiT. RelekarK. A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma.J. Immunother.201134650951510.1097/CJI.0b013e31821dcefd21654521
     [Google Scholar]
  48. GuenterbergK.D. GrignolV.P. RelekarK.V. A pilot study of bevacizumab and interferon-α2b in ocular melanoma.Am. J. Clin. Oncol.2011341879110.1097/COC.0b013e3181d2ed6720458209
     [Google Scholar]
  49. TarhiniA.A. CherianJ. MoschosS.J. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.J. Clin. Oncol.201230332232810.1200/JCO.2011.37.539422184371
     [Google Scholar]
  50. SmallE.J. TchekmedyianN.S. RiniB.I. FongL. LowyI. AllisonJ.P. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.Clin. Cancer Res.20071361810181510.1158/1078‑0432.CCR‑06‑231817363537
     [Google Scholar]
  51. SwitzerB. PuzanovI. SkitzkiJ.J. HamadL. ErnstoffM.S. Managing metastatic melanoma in 2022: A clinical review.JCO Oncol. Pract.202218533535110.1200/OP.21.0068635133862
     [Google Scholar]
  52. HodiF.S. O’DayS.J. McDermottD.F. Improved survival with ipilimumab in patients with metastatic melanoma.N. Engl. J. Med.2010363871172310.1056/NEJMoa100346620525992
     [Google Scholar]
  53. EggermontA.M.M. Chiarion-SileniV. GrobJ.J. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial.Lancet Oncol.201516552253010.1016/S1470‑2045(15)70122‑125840693
     [Google Scholar]
  54. LarkinJ. Chiarion-SileniV. GonzalezR. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma.N. Engl. J. Med.2019381161535154610.1056/NEJMoa191083631562797
     [Google Scholar]
  55. WolchokJ.D. Chiarion-SileniV. GonzalezR. CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.J. Clin. Oncol.2021391595066
     [Google Scholar]
  56. AsciertoP.A. Del VecchioM. RobertC. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: A randomised, double-blind, multicentre, phase 3 trial.Lancet Oncol.201718561162210.1016/S1470‑2045(17)30231‑028359784
     [Google Scholar]
  57. AsciertoP.A. Del VecchioM. MackiewiczA. Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma.J. Immunother. Cancer202081e00039110.1136/jitc‑2019‑00039132503946
     [Google Scholar]
  58. RomanoE. Kusio-KobialkaM. FoukasP.G. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.Proc. Natl. Acad. Sci. USA2015112196140614510.1073/pnas.141732011225918390
     [Google Scholar]
  59. ReilleyM.J. MorrowB. AgerC.R. LiuA. HongD.S. CurranM.A. TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma.J. Immunother. Cancer20197132310.1186/s40425‑019‑0811‑x31771649
     [Google Scholar]
  60. TarhiniA. LinY. LinH. Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: Safety, efficacy and impact on T-cell repertoire.J. Immunother. Cancer20186111210.1186/s40425‑018‑0428‑530352626
     [Google Scholar]
  61. RobertC. RibasA. SchachterJ. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): Post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.Lancet Oncol.20192091239125110.1016/S1470‑2045(19)30388‑231345627
     [Google Scholar]
  62. RobertC. LongG.V. BradyB. Nivolumab in previously untreated melanoma without BRAF mutation.N. Engl. J. Med.2015372432033010.1056/NEJMoa141208225399552
     [Google Scholar]
  63. HodiF.S. ChesneyJ. PavlickA.C. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.Lancet Oncol.201617111558156810.1016/S1470‑2045(16)30366‑727622997
     [Google Scholar]
  64. LongG.V. AtkinsonV. LoS. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: A multicentre randomised phase 2 study.Lancet Oncol.201819567268110.1016/S1470‑2045(18)30139‑629602646
     [Google Scholar]
  65. TawbiH.A. ForsythP.A. AlgaziA. Combined nivolumab and ipilimumab in melanoma metastatic to the brain.N. Engl. J. Med.2018379872273010.1056/NEJMoa180545330134131
     [Google Scholar]
  66. SchvartsmanG. TarantoP. GlitzaI.C. AgarwalaS.S. AtkinsM.B. BuzaidA.C. Management of metastatic cutaneous melanoma: Updates in clinical practice.Ther. Adv. Med. Oncol.201911175883591985166310.1177/175883591985166331205512
     [Google Scholar]
  67. PiulatsJ.M. EspinosaE. de la Cruz MerinoL. Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: An open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402).J. Clin. Oncol.202139658659810.1200/JCO.20.0055033417511
     [Google Scholar]
  68. NajjarY.G. NavrazhinaK. DingF. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: A multicenter, retrospective study.J. Immunother. Cancer202081e00033110.1136/jitc‑2019‑00033132581057
     [Google Scholar]
  69. PelsterM.S. GruschkusS.K. BassettR. Nivolumab and ipilimumab in metastatic uveal melanoma: Results from a single-arm phase II study.J. Clin. Oncol.202139659960710.1200/JCO.20.0060533125309
     [Google Scholar]
  70. TriebelF.A. A novel lymphocyte activation gene closely related to CD4.J. Exp. Med.199617112
     [Google Scholar]
  71. HuangC.T. WorkmanC.J. FliesD. Role of LAG-3 in regulatory T cells.Immunity200421450351310.1016/j.immuni.2004.08.01015485628
     [Google Scholar]
  72. HannierS. TournierM. BismuthG. TriebelF. CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling.J. Immunol.199816184058406510.4049/jimmunol.161.8.40589780176
     [Google Scholar]
  73. BjoernJ. LyngaaR. AndersenR. Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.Oncotarget2017816270622707410.18632/oncotarget.1600328423678
     [Google Scholar]
  74. WooS.R. TurnisM.E. GoldbergM.V. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.Cancer Res.201272491792710.1158/0008‑5472.CAN‑11‑162022186141
     [Google Scholar]
  75. RomanoE. MichielinO. VoelterV. MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: Results of a Phase I trial.J. Transl. Med.20141219710.1186/1479‑5876‑12‑9724726012
     [Google Scholar]
  76. BrignoneC. GutierrezM. MeftiF. First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity.J. Transl. Med.2010817110.1186/1479‑5876‑8‑7120653948
     [Google Scholar]
  77. BrignoneC. EscudierB. GrygarC. MarcuM. TriebelF. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma.Clin. Cancer Res.200915196225623110.1158/1078‑0432.CCR‑09‑006819755389
     [Google Scholar]
  78. HahnA.W. GillD.M. PalS.K. AgarwalN. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.Immunotherapy20179868169210.2217/imt‑2017‑002428653573
     [Google Scholar]
  79. LipsonE. Initial experience administering BMS-986016, a monoclonal antibody that targets lymphocyte activation gene (LAG)-3, alone and in combination with nivolumab to patients with hematologic and solid malignancies.J. Immunother. Cancer20164Suppl. 1232
     [Google Scholar]
  80. AsciertoPA MeleroI BhatiaS Initial efficacy of antilymphocyte activation gene-3 (anti-LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti-PD-1/PD-L1 therapy2017351595200
     [Google Scholar]
  81. AsciertoP.A. BonoP. BhatiaS. Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti-PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations.Ann. Oncol.201728v611v61210.1093/annonc/mdx440.011
     [Google Scholar]
  82. EvanJ.L. TawbiH.A.H. SchadendorfD. Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).J. Clin. Oncol.20213915_suppl.950310.1200/JCO.2021.39.15_suppl.9503
     [Google Scholar]
  83. TawbiH.A. SchadendorfD. LipsonE.J. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma.N. Engl. J. Med.20223861243410.1056/NEJMoa210997034986285
     [Google Scholar]
  84. Long GeorginaV. HodiF.S. LipsonE.J. Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047).J. Clin. Oncol.20224036_suppl.10.1200/JCO.2022.40.36_suppl.360385
     [Google Scholar]
  85. Study of efficacy and safety of novel spartalizumab combinations in patients with previously treated unresectable or metastatic melanoma (PLATforM)NCT034849232024
     [Google Scholar]
  86. Treatment Clinical Trials for Melanoma Treatment Clinical Trials for Melanoma.National Cancer Institute.Available from: https://www.cancer.gov/research/participate/clinical-trials/disease/melanoma/treatment?pn=1
    [Google Scholar]
  87. Dose escalation study of a PD1-LAG3 bispecific antibody in patients with advanced and/or metastatic solid tumorsNCT041405002025
     [Google Scholar]
  88. RosenbergS.A. RestifoN.P. YangJ.C. MorganR.A. DudleyM.E. Adoptive cell transfer: A clinical path to effective cancer immunotherapy.Nat. Rev. Cancer20088429930810.1038/nrc235518354418
     [Google Scholar]
  89. SarnaikA.A. HamidO. KhushalaniN.I. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma.J. Clin. Oncol.202139242656266610.1200/JCO.21.0061233979178
     [Google Scholar]
  90. Betof WarnerA. CorrieP.G. HamidO. Tumor-infiltrating lymphocyte therapy in melanoma: Facts to the future.Clin. Cancer Res.202329101835185410.1158/1078‑0432.CCR‑22‑192236485001
     [Google Scholar]
  91. CarrenoB.M. MagriniV. Becker-HapakM. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.Science2015348623680380810.1126/science.aaa382825837513
     [Google Scholar]
  92. HuZ. LeetD.E. AllesøeR.L. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma.Nat. Med.202127351552510.1038/s41591‑020‑01206‑433479501
     [Google Scholar]
  93. Moderna and Merck announce mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA® (pembrolizumab), met primary efficacy endpoint in phase 2b KEYNOTE-942 trial2022Available from: https://www.merck.com/news/moderna-and-merck-announce-mrna-4157-v940-an-investigational-personalized-mrna-cancer-vaccine-in-combination-with-keytruda-pembrolizumab-met-primary-efficacy-endpoint-in-phase-2b-keynote-94/
  94. InamdarG.S. MadhunapantulaS.V. RobertsonG.P. Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail.Biochem. Pharmacol.201080562463710.1016/j.bcp.2010.04.02920450891
     [Google Scholar]
  95. LongG.V. StroyakovskiyD. GogasH. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.N. Engl. J. Med.2014371201877188810.1056/NEJMoa140603725265492
     [Google Scholar]
  96. TrojanielloC. LukeJ.J. AsciertoP.A. Therapeutic advancements across clinical stages in melanoma, with a focus on targeted immunotherapy.Front. Oncol.20211167072610.3389/fonc.2021.67072634178657
     [Google Scholar]
  97. HamidO. CoweyC.L. OffnerM. FariesM. CarvajalR.D. Efficacy, safety, and tolerability of approved combination BRAF and MEK inhibitor regimens for BRAF-mutant melanoma.Cancers20191111164210.3390/cancers1111164231653096
     [Google Scholar]
  98. HeinrichM.C. GriffithD.J. DrukerB.J. WaitC.L. OttK.A. ZiglerA.J. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.Blood200096392593210.1182/blood.V96.3.92510910906
     [Google Scholar]
  99. CarvajalR.D. AntonescuC.R. WolchokJ.D. KIT as a therapeutic target in metastatic melanoma.JAMA2011305222327233410.1001/jama.2011.74621642685
     [Google Scholar]
  100. NassarK.W. TanA.C. The mutational landscape of mucosal melanoma.Semin. Cancer Biol.202061139148
     [Google Scholar]
  101. JakobJ.A. BassettR.L. NgC.S. NRAS mutation status is an independent prognostic factor in metastatic melanoma.Cancer2012118164014402310.1002/cncr.2672422180178
     [Google Scholar]
  102. MandalàM. MerelliB. MassiD. NRAS in melanoma: Targeting the undruggable target.Crit. Rev. Oncol. Hematol.201492210712210.1016/j.critrevonc.2014.05.00524985059
     [Google Scholar]
  103. Al MahiA. AblainJ. RAS pathway regulation in melanoma.Dis. Model. Mech.2022152dmm04922910.1242/dmm.04922935234863
     [Google Scholar]
  104. KirkwoodJ.M. AgarwalaS.S. Systemic cytotoxic and biologic therapy of melanoma.PPO Updates19937119931996
     [Google Scholar]
  105. GloverD. IbrahimJ. KirkwoodJ. Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma.Melanoma Res.200313661962610.1097/00008390‑200312000‑0001214646626
     [Google Scholar]
  106. EvansL.M. CasperE.S. RosenbluthR. Phase II trial of carboplatin in advanced malignant melanoma.Cancer Treat. Rep.19877121711723542209
     [Google Scholar]
  107. DasariS. TchounwouP.B. Cisplatin in cancer therapy: Molecular mechanisms of action.Eur. J. Pharmacol.201474036437810.1016/j.ejphar.2014.07.02525058905
     [Google Scholar]
  108. GüvenK. KittlerH. WolffK. PehambergerH. Cisplatin and carboplatin combination as second-line chemotherapy in dacarbazine-resistant melanoma patients.Melanoma Res.200111441141510.1097/00008390‑200108000‑0001211479430
     [Google Scholar]
  109. WiernikP.H. Taxol in malignant melanoma.J. Natl. Cancer Inst. Monogr.199315185187
     [Google Scholar]
  110. EinzigA.I. HochsterH. WiernikP.H. A phase II study of taxol in patients with malignant melanoma.Invest. New Drugs199191596410.1007/BF001945461673965
     [Google Scholar]
  111. LeghaS.S. RingS. PapadopoulosN. RaberM. BenjaminR.S. A phase II trial of taxol in metastatic melanoma.Cancer199065112478248110.1002/1097‑0142(19900601)65:11<2478:AID‑CNCR2820651114>3.0.CO;2‑S1970948
     [Google Scholar]
  112. WeissR.B. DonehowerR.C. WiernikP.H. Hypersensitivity reactions from taxol.J. Clin. Oncol.1990871263126810.1200/JCO.1990.8.7.12631972736
     [Google Scholar]
  113. YamamotoY. KawanoI. IwaseH. Nab-paclitaxel for the treatment of breast cancer: Efficacy, safety, and approval.OncoTargets Ther.2011412313610.2147/OTT.S1383621792318
     [Google Scholar]
  114. HershE.M. Del VecchioM. BrownM.P. A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.Ann. Oncol.201526112267227410.1093/annonc/mdv32426410620
     [Google Scholar]
  115. EggermontA.M.M. KirkwoodJ.M. Re-evaluating the role of dacarbazine in metastatic melanoma: What have we learned in 30 years?Eur. J. Cancer200440121825183610.1016/j.ejca.2004.04.03015288283
     [Google Scholar]
  116. WilsonM.A. SchuchterL.M. Chemotherapy for melanoma.Melanoma201616720922910.1007/978‑3‑319‑22539‑5_8
     [Google Scholar]
  117. HuncharekM. CaubetJ.F. McGarryR. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: A meta-analysis of 3273 patients from 20 randomized trials.Melanoma Res.2001111758110.1097/00008390‑200102000‑0000911254118
     [Google Scholar]
  118. CrosbyT. Systemic treatments for metastatic cutaneous melanoma.Cochrane Database Syst. Rev.199620146
     [Google Scholar]
  119. BajettaE. VecchioM.D. Bernard-MartyC. Metastatic melanoma: Chemotherapy.Semin. Oncol.200229542744510.1053/sonc.2002.35238
     [Google Scholar]
  120. QuirtI. VermaS. PetrellaT. BakK. CharetteM. Temozolomide for the treatment of metastatic melanoma: A systematic review.Oncologist20071291114112310.1634/theoncologist.12‑9‑111417914081
     [Google Scholar]
  121. MiddletonM.R. GrobJ.J. AaronsonN. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.J. Clin. Oncol.200018115816610.1200/JCO.2000.18.1.15810623706
     [Google Scholar]
  122. PaulM.J. SummersY. CalvertA.H. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma.Melanoma Res.200212217517810.1097/00008390‑200204000‑0001111930115
     [Google Scholar]
  123. BhatiaS. TykodiS.S. ThompsonJ.A. Treatment of metastatic melanoma: An overview.Oncology200923648849619544689
     [Google Scholar]
  124. RibasA. HodiF.S. CallahanM. KontoC. WolchokJ. Hepatotoxicity with combination of vemurafenib and ipilimumab.N. Engl. J. Med.2013368141365136610.1056/NEJMc130233823550685
     [Google Scholar]
  125. Hu-LieskovanS. MokS. MorenoB.H. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma.Sci. Transl. Med.20157279279ra4110.1126/scitranslmed.aaa4691
     [Google Scholar]
  126. LelliottE.J. McArthurG.A. OliaroJ. SheppardK.E. Immunomodulatory effects of BRAF, MEK, and CDK4/6 inhibitors: Implications for combining targeted therapy and immune checkpoint blockade for the treatment of melanoma.Front. Immunol.20211266173710.3389/fimmu.2021.66173734025662
     [Google Scholar]
  127. FerrucciP.F. Di GiacomoA.M. Del VecchioM. KEYNOTE-022 part 3: A randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma.J. Immunother. Cancer202082e00180610.1136/jitc‑2020‑00180633361337
     [Google Scholar]
  128. LongGV LebbeC AtkinsonV The anti-PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i201938595311
     [Google Scholar]
  129. Stachyra-StrawaP. CiesielkaM. JaniszewskiM. Grzybowska-SzatkowskaL. The role of immunotherapy and molecular targeted therapy in the treatment of melanoma (Review).Oncol. Rep.202146215810.3892/or.2021.810934109986
     [Google Scholar]
  130. WeidnerN. SempleJ.P. WelchW.R. FolkmanJ. Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma.N. Engl. J. Med.199132411810.1056/NEJM1991010332401011701519
     [Google Scholar]
  131. WeidnerN. FolkmanJ. PozzaF. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma.J. Natl. Cancer Inst.199284241875188710.1093/jnci/84.24.18751281237
     [Google Scholar]
  132. FolkmanJ. Angiogenesis in cancer, vascular, rheumatoid and other disease.Nat. Med.199511273010.1038/nm0195‑277584949
     [Google Scholar]
  133. ImaoT. EgawaM. TakashimaH. KoshidaK. NamikiM. Inverse correlation of microvessel density with metastasis and prognosis in renal cell carcinoma.Int. J. Urol.2004111194895310.1111/j.1442‑2042.2004.00931.x15509196
     [Google Scholar]
  134. BusamK.J. BerwickM. BlessingK. Tumor vascularity is not a prognostic factor for malignant melanoma of the skin.Am. J. Pathol.19951474104910567573350
     [Google Scholar]
  135. CarnochanP. BriggsJ.C. WestburyG. DaviesA.J.S. The vascularity of cutaneous melanoma: A quantitative histological study of lesions 0.85-1.25 mm in thickness.Br. J. Cancer199164110210710.1038/bjc.1991.2501854608
     [Google Scholar]
  136. NeitzelL.T. NeitzelC.D. MageeK.L. MalafaM.P. Angiogenesis correlates with metastasis in melanoma.Ann. Surg. Oncol.199961707410.1007/s10434‑999‑0070‑z10030417
     [Google Scholar]
  137. GeorganakiM. van HoorenL. DimbergA. Vascular targeting to increase the efficiency of immune checkpoint blockade in cancer.Front. Immunol.20189308110.3389/fimmu.2018.0308130627131
     [Google Scholar]
  138. SongY. FuY. XieQ. ZhuB. WangJ. ZhangB. Anti-angiogenic agents in combination with immune checkpoint inhibitors: A promising strategy for cancer treatment.Front. Immunol.202011195610.3389/fimmu.2020.0195632983126
     [Google Scholar]
  139. AranceA. de la Cruz-MerinoL. PetrellaT.M. Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination.J. Clin. Oncol.2023411758510.1200/JCO.22.0022135867951
     [Google Scholar]
  140. Welcome to NCCN.org.Available from: https://www.nccn.org/
  141. Cancer immunotherapy guidelines cutaneous melanoma - Current algorithms2018Available from: https://www.sitcancer.org/research/cancer-immunotherapy-guidelines/melanoma/currentalgorithms
  142. AtkinsM.B. LeeS.J. ChmielowskiB. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: The DREAMseq trial—ECOG-ACRIN EA6134.J. Clin. Oncol.202341218619710.1200/JCO.22.0176336166727
     [Google Scholar]
  143. RobertC DutriauxC OppongFB Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAFV600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN)20244217LBA9503-LBA9503-2222
     [Google Scholar]
  144. HiekenT.J. KreidiehF. Aedo-LopezV. BlockM.S. McArthurG.A. AmariaR.N. Neoadjuvant immunotherapy in melanoma: The paradigm shift.Am. Soc. Clin. Oncol. Educ. Book20234343e390614e39062210.1200/EDBK_39061437116111
     [Google Scholar]
  145. PatelS.P. OthusM. ChenY. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma.N. Engl. J. Med.2023388981382310.1056/NEJMoa221143736856617
     [Google Scholar]
  146. AmariaR.N. PostowM. BurtonE.M. Neoadjuvant relatlimab and nivolumab in resectable melanoma.Nature2022611793415516010.1038/s41586‑022‑05368‑836289334
     [Google Scholar]
  147. WhijaeR. ChenP. ReubenA. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.J. Transl. Med.2017937910.1126/scitranslmed.aah3560
     [Google Scholar]
  148. ErstadD.J. WittR.G. WargoJ.A. Neoadjuvant therapy for melanoma: New and evolving concepts.Clin. Adv. Hematol. Oncol.2022201475535060962
     [Google Scholar]
  149. RozemanE.A. MenziesA.M. van AkkooiA.C.J. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): A multicentre, phase 2, randomised, controlled trial.Lancet Oncol.201920794896010.1016/S1470‑2045(19)30151‑231160251
     [Google Scholar]
  150. SmithM.J.F. SmithH.G. JoshiK. The impact of effective systemic therapies on surgery for stage IV melanoma.Eur. J. Cancer2018103243110.1016/j.ejca.2018.08.00830196107
     [Google Scholar]
  151. BlankensteinS.A. AartsM.J.B. van den BerkmortelF.W.P.J. Surgery for unresectable stage IIIC and IV melanoma in the era of new systemic therapy.Cancers2020125117610.3390/cancers1205117632392717
     [Google Scholar]
  152. BelloD.M. PanageasK.S. HollmannT. Survival outcomes after metastasectomy in melanoma patients categorized by response to checkpoint blockade.Ann. Surg. Oncol.20202741180118810.1245/s10434‑019‑08099‑931848819
     [Google Scholar]
  153. Ch’ngS. UyulmazS. CarlinoM.S. Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies.Eur. J. Cancer202115381510.1016/j.ejca.2021.04.03734126335
     [Google Scholar]
  154. PaulS. AltorkiN.K. ShengS. Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: A propensity-matched analysis from the STS database.J. Thorac. Cardiovasc. Surg.2010139236637810.1016/j.jtcvs.2009.08.02620106398
     [Google Scholar]
  155. RoseD.M. EssnerR. HughesT.M. Surgical resection for metastatic melanoma to the liver: The John Wayne Cancer Institute and Sydney Melanoma Unit experience.Arch. Surg.2001136895095510.1001/archsurg.136.8.95011485537
     [Google Scholar]
  156. LeungA.M. HariD.M. MortonD.L. Surgery for distant melanoma metastasis.Cancer J.201218217618410.1097/PPO.0b013e31824bc98122453019
     [Google Scholar]
  157. FlahertyD.C. DeutschG.B. KirchoffD.D. Adrenalectomy for metastatic melanoma: Current role in the age of nonsurgical treatments.Am. Surg.201581101005100910.1177/00031348150810101926463298
     [Google Scholar]
  158. RussoA.E. UntchB.R. KrisM.G. Adrenal metastasectomy in the presence and absence of extraadrenal metastatic disease.Ann. Surg.2019270237337710.1097/SLA.000000000000274929578911
     [Google Scholar]
  159. KreidiehF.Y. TawbiH.A. Current and emerging options for patients with melanoma brain metastases.Clin. Adv. Hematol. Oncol.2022201061962736206074
     [Google Scholar]
  160. TawbiH.A. BoutrosC. KokD. RobertC. McArthurG. New era in the management of melanoma brain metastases.Am. Soc. Clin. Oncol. Educ. Book2018383874175010.1200/EDBK_20081930231345
     [Google Scholar]
  161. RishiA. YuH.H.M. Current treatment of melanoma brain metastasis.Curr. Treat. Options Oncol.20202164510.1007/s11864‑020‑00733‑z32350685
     [Google Scholar]
  162. GazzeriR. NalavenkataS. TeoC. Minimally invasive key-hole approach for the surgical treatment of single and multiple brain metastases.Clin. Neurol. Neurosurg.201412311712610.1016/j.clineuro.2014.05.01025012023
     [Google Scholar]
  163. HatibogluM.A. WildrickD.M. SawayaR. The role of surgical resection in patients with brain metastases.Ecancermedicalscience2013730823634178
     [Google Scholar]
  164. YamamotoM. KawabeT. SatoY. Stereotactic radiosurgery for patients with multiple brain metastases: A case-matched study comparing treatment results for patients with 2-9 versus 10 or more tumors.J. Neurosurg.2014121Suppl. 2162510.3171/2014.8.GKS14142125434933
     [Google Scholar]
  165. TawbiH.A. ForsythP.A. HodiF.S. Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204).Neuro-oncol.202123111961197310.1093/neuonc/noab09433880555
     [Google Scholar]
  166. MandalàM. De LoguF. MerelliB. NassiniR. MassiD. Immunomodulating property of MAPK inhibitors: From translational knowledge to clinical implementation.Lab. Invest.201797216617510.1038/labinvest.2016.13227991907
     [Google Scholar]
  167. GutzmerR. StroyakovskiyD. GogasH. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): Primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.Lancet2020395102401835184410.1016/S0140‑6736(20)30934‑X32534646
     [Google Scholar]
  168. Phase II study of nivolumab in combination with relatlimab in patients with active melanoma brain metastasesNCT057046472024
     [Google Scholar]
  169. S8 immunotoxicity studies for human pharmaceuticals2006Available from: https://www.fda.gov/media/72047/download
  170. CarlosG. AnforthR. ClementsA. Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma.JAMA Dermatol.2015151101103110910.1001/jamadermatol.2015.174526200476
     [Google Scholar]
  171. HaanenJ. ObeidM. SpainL. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.Ann. Oncol.202233121217123810.1016/j.annonc.2022.10.00136270461
     [Google Scholar]
  172. LarkinJ. Chiarion-SileniV. GonzalezR. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.N. Engl. J. Med.20153731233410.1056/NEJMoa150403026027431
     [Google Scholar]
  173. WolchokJ.D. NeynsB. LinetteG. Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study.Lancet Oncol.201011215516410.1016/S1470‑2045(09)70334‑120004617
     [Google Scholar]
  174. EggermontA.M.M. Chiarion-SileniV. GrobJ.J. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy.N. Engl. J. Med.20163751845185510.1056/NEJMoa1611299
     [Google Scholar]
  175. NaidooJ. PageD.B. LiB.T. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.Ann. Oncol.201526122375239110.1093/annonc/mdv38326371282
     [Google Scholar]
  176. BrahmerJ. ReckampK.L. BaasP. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer.N. Engl. J. Med.2015373212313510.1056/NEJMoa150462726028407
     [Google Scholar]
  177. RibasA. PuzanovI. DummerR. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial.Lancet Oncol.201516890891810.1016/S1470‑2045(15)00083‑226115796
     [Google Scholar]
  178. EigentlerT.K. HasselJ.C. BerkingC. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy.Cancer Treat. Rev.20164571810.1016/j.ctrv.2016.02.00326922661
     [Google Scholar]
  179. WeberJ.S. HodiF.S. WolchokJ.D. Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma.J. Clin. Oncol.201735778579210.1200/JCO.2015.66.138928068177
     [Google Scholar]
  180. HorvatT.Z. AdelN.G. DangT.O. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center.J. Clin. Oncol.201533283193319810.1200/JCO.2015.60.844826282644
     [Google Scholar]
  181. GaruttiM. BergnachM. PoleselJ. PalmeroL. PizzichettaM.A. PuglisiF. BRAF and MEK inhibitors and their toxicities: A meta-analysis.Cancers (Basel)202215114110.3390/cancers1501014136612138
     [Google Scholar]
  182. MincuR.I. MahabadiA.A. MichelL. Cardiovascular adverse events associated with BRAF and MEK inhibitors: A systematic review and meta-analysis.JAMA Netw. Open201928e19889010.1001/jamanetworkopen.2019.889031397860
     [Google Scholar]
  183. ArangalageD. DegrauweN. MichielinO. MonneyP. ÖzdemirB.C. Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors.Cancer Treat. Rev.202110010228210.1016/j.ctrv.2021.10228234438238
     [Google Scholar]
  184. Zelboraf. European Medicines Agency 2013Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/zelboraf
  185. KreidiehF. McQuadeJ. Novel insights into cardiovascular toxicity of cancer targeted and immune therapies: Beyond ischemia with non-obstructive coronary arteries (INOCA).In: Am. Heart J. Plus20244010037410.1016/j.ahjo.2024.10037438510501
     [Google Scholar]
  186. BanksM. CrowellK. ProctorA. JensenB.C. Cardiovascular effects of the MEK inhibitor, trametinib: A case report, literature review, and consideration of mechanism.Cardiovasc. Toxicol.201717448749310.1007/s12012‑017‑9425‑z28861837
     [Google Scholar]
  187. DummerR. RinderknechtJ. GoldingerS.M. Ultraviolet A and photosensitivity during vemurafenib therapy.N. Engl. J. Med.2012366548048110.1056/NEJMc111375222296092
     [Google Scholar]
  188. HauschildA. GrobJ.J. DemidovL.V. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial.Lancet2012380983935836510.1016/S0140‑6736(12)60868‑X22735384
     [Google Scholar]
  189. ChapmanP.B. HauschildA. RobertC. Improved survival with vemurafenib in melanoma with BRAF V600E mutation.N. Engl. J. Med.2011364262507251610.1056/NEJMoa110378221639808
     [Google Scholar]
  190. McArthurG.A. ChapmanP.B. RobertC. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study.Lancet Oncol.201415332333210.1016/S1470‑2045(14)70012‑924508103
     [Google Scholar]
  191. FlahertyL. HamidO. LinetteG. A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States.Cancer J.2014201182410.1097/PPO.000000000000002424445759
     [Google Scholar]
  192. LivingstoneE. ZimmerL. VaubelJ. SchadendorfD. BRAF, MEK and KIT inhibitors for melanoma: Adverse events and their management.Chin Clin Oncol20143329925841455
     [Google Scholar]
/content/journals/cpd/10.2174/0113816128341628250519093548
Loading
New Standards in the Treatment of Advanced Metastatic Melanoma: Immunotherapy and BRAF-Targeted Therapies as Emerging Paradigms
Curr. Pharm. Des. 32, 285 (2026); https://doi.org/10.2174/0113816128341628250519093548
/content/journals/cpd/10.2174/0113816128341628250519093548
/content/journals/cpd/10.2174/0113816128341628250519093548
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Advanced melanoma; brain metastases; cancer vaccine; immune checkpoint inhibitor; targeted therapy; tumor-infiltrating lymphocytes

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test